_id
69148a8accc777a4e85d9918
Ticker
PBMWW
Name
Psyence Biomedical Ltd. Warrant
Exchange
NASDAQ
Address
121 Richmond Street West, Toronto, ON, Canada, M5H2K1
Country
USA
Sector
Industry
Currency
USD
Website
https://www.psyencebiomed.com
Description
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Last Close
0.024
Volume
48628
Current Price
0.016
Change
0.0018
Last Updated
2026-01-06T08:55:04.482Z
Image
data:image/webp;base64,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
Ipo Date
2024-01-26T00:00:00.000Z
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
1506307
Operating Income
-1506307
Interest Expense
2753
Pretax Income
-753254
Net Income
-753254
Eps
-0.40236831154706787
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
682991
Cash
7149985
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
7629455
Property Plant Equipment
8690
Total Assets
12810145
Payables
235868
Short Term Debt
-
Long Term Debt
-
Total Liabilities
943068
Equity
11867077
Bs_currency_symbol
USD
Depreciation
-
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
USD
PE
-
PB
0.002524026430434386
ROE
-6.3474265819628535
ROA
-5.88013640751139
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
1506307
Quarters > 0 > income Statement > operating Income
-1506307
Quarters > 0 > income Statement > interest Expense
2753
Quarters > 0 > income Statement > pretax Income
-753254
Quarters > 0 > income Statement > net Income
-753254
Quarters > 0 > income Statement > eps
-0.40236831154706787
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1872051
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
682991
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
7149985
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
7629455
Quarters > 0 > balance Sheet > property Plant Equipment
8690
Quarters > 0 > balance Sheet > total Assets
12810145
Quarters > 0 > balance Sheet > payables
235868
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
943068
Quarters > 0 > balance Sheet > equity
11867077
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-753254
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.40236831154706787
Quarters > 0 > ratios > PB
0.002524026430434386
Quarters > 0 > ratios > ROE
-6.3474265819628535
Quarters > 0 > ratios > ROA
-5.88013640751139
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
1157118
Quarters > 1 > income Statement > operating Income
-1157118
Quarters > 1 > income Statement > interest Expense
3715
Quarters > 1 > income Statement > pretax Income
141473
Quarters > 1 > income Statement > net Income
141473
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
146204
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
1298591
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1932519
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
125080
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
2243372
Quarters > 1 > balance Sheet > property Plant Equipment
10126
Quarters > 1 > balance Sheet > total Assets
2253498
Quarters > 1 > balance Sheet > payables
805613
Quarters > 1 > balance Sheet > short Term Debt
2500862
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3508604
Quarters > 1 > balance Sheet > equity
-1255106
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-
Quarters > 1 > cash Flow > depreciation
1016
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-
Quarters > 1 > cash Flow > capital Expenditures
-
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-11.271796963762423
Quarters > 1 > ratios > ROA
6.2779288022443325
Quarters > 1 > ratios > FCF
-
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
40
Quarters > 2 > quarter
2024-09-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
1157118
Quarters > 2 > income Statement > operating Income
-1157118
Quarters > 2 > income Statement > interest Expense
3715
Quarters > 2 > income Statement > pretax Income
141473
Quarters > 2 > income Statement > net Income
141473
Quarters > 2 > income Statement > eps
1.8612909167456058
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
76008
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1302306
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
1932519
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2243372
Quarters > 2 > balance Sheet > property Plant Equipment
10126
Quarters > 2 > balance Sheet > total Assets
2253498
Quarters > 2 > balance Sheet > payables
805613
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3508604
Quarters > 2 > balance Sheet > equity
-1255106
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
141473
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
1.8612909167456058
Quarters > 2 > ratios > PB
-0.0009689444556874081
Quarters > 2 > ratios > ROE
-11.271796963762423
Quarters > 2 > ratios > ROA
6.2779288022443325
Quarters > 2 > ratios > FCF
-
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2023-09-30
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
176165
Quarters > 3 > income Statement > operating Income
-173845.36
Quarters > 3 > income Statement > interest Expense
27936
Quarters > 3 > income Statement > pretax Income
-305604.36
Quarters > 3 > income Statement > net Income
-314030.75
Quarters > 3 > income Statement > eps
-0.024639101925200343
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
12745219
Quarters > 3 > income Statement > income Tax Expense
8426.4
Quarters > 3 > income Statement > EBITDA
-281746
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-305604.36
Quarters > 3 > income Statement > currency_symbol
CAD
Quarters > 3 > balance Sheet > cash
598382
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
18686
Quarters > 3 > balance Sheet > inventories
2
Quarters > 3 > balance Sheet > total Current Assets
665777
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
665777
Quarters > 3 > balance Sheet > payables
910077.25
Quarters > 3 > balance Sheet > short Term Debt
733094
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1643171
Quarters > 3 > balance Sheet > equity
-977394.25
Quarters > 3 > balance Sheet > currency_symbol
CAD
Quarters > 3 > cash Flow > net Income
-309682
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
CAD
Quarters > 3 > ratios > PE
-0.024639101925200343
Quarters > 3 > ratios > PB
-0.20863996693248402
Quarters > 3 > ratios > ROE
32.129383818249394
Quarters > 3 > ratios > ROA
-47.16755760562471
Quarters > 3 > ratios > FCF
-
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
38
Annuals > 0 > quarter
2025-03-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
3663022
Annuals > 0 > income Statement > operating Income
-3663022
Annuals > 0 > income Statement > interest Expense
9270
Annuals > 0 > income Statement > pretax Income
1011790
Annuals > 0 > income Statement > net Income
1011790
Annuals > 0 > income Statement > eps
1.7812545662924435
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
568021
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
4588295
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
6135166
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
137348
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
6560274
Annuals > 0 > balance Sheet > property Plant Equipment
11096
Annuals > 0 > balance Sheet > total Assets
7316370
Annuals > 0 > balance Sheet > payables
261937
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
594366
Annuals > 0 > balance Sheet > equity
6722004
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
1011790
Annuals > 0 > cash Flow > depreciation
4268
Annuals > 0 > cash Flow > change In Working Capital
-386203
Annuals > 0 > cash Flow > cash From Operations
-3734238
Annuals > 0 > cash Flow > capital Expenditures
9877
Annuals > 0 > cash Flow > cash From Investing
-16230
Annuals > 0 > cash Flow > cash From Financing
9152446
Annuals > 0 > cash Flow > net Change In Cash
5401978
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
1.7812545662924435
Annuals > 0 > ratios > PB
0.0016815845244959689
Annuals > 0 > ratios > ROE
15.051910114900258
Annuals > 0 > ratios > ROA
13.829125645641213
Annuals > 0 > ratios > FCF
-3744115
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
70
Annuals > 1 > quarter
2024-03-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
46694454
Annuals > 1 > income Statement > operating Income
-45812976
Annuals > 1 > income Statement > interest Expense
52941
Annuals > 1 > income Statement > pretax Income
-51159047
Annuals > 1 > income Statement > net Income
-51159048
Annuals > 1 > income Statement > eps
-3.820502635456552
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
13390659
Annuals > 1 > income Statement > income Tax Expense
1
Annuals > 1 > income Statement > EBITDA
-50173581
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-5346071
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
733188
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
41747
Annuals > 1 > balance Sheet > inventories
322126
Annuals > 1 > balance Sheet > total Current Assets
1126672
Annuals > 1 > balance Sheet > property Plant Equipment
5487
Annuals > 1 > balance Sheet > total Assets
1132159
Annuals > 1 > balance Sheet > payables
562352
Annuals > 1 > balance Sheet > short Term Debt
10447889
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
12104699
Annuals > 1 > balance Sheet > equity
-10972540
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-51159048
Annuals > 1 > cash Flow > depreciation
240
Annuals > 1 > cash Flow > change In Working Capital
-1172951
Annuals > 1 > cash Flow > cash From Operations
-2945367
Annuals > 1 > cash Flow > capital Expenditures
5727
Annuals > 1 > cash Flow > cash From Investing
-5727
Annuals > 1 > cash Flow > cash From Financing
2350000
Annuals > 1 > cash Flow > net Change In Cash
-601092
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-3.820502635456552
Annuals > 1 > ratios > PB
-0.024285545015101336
Annuals > 1 > ratios > ROE
466.24617454117276
Annuals > 1 > ratios > ROA
-4518.715834083376
Annuals > 1 > ratios > FCF
-2951094
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2023-03-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
3234869
Annuals > 2 > income Statement > operating Income
-3233315
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-3206403
Annuals > 2 > income Statement > net Income
-3206403
Annuals > 2 > income Statement > eps
-0.25157692464915665
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
12745219
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-3233315
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
26912
Annuals > 2 > income Statement > currency_symbol
CAD
Annuals > 2 > balance Sheet > cash
1334280
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
149369
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
1590255
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
1590255
Annuals > 2 > balance Sheet > payables
1628143
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
1790700
Annuals > 2 > balance Sheet > equity
-200445
Annuals > 2 > balance Sheet > currency_symbol
CAD
Annuals > 2 > cash Flow > net Income
-3206403
Annuals > 2 > cash Flow > depreciation
0
Annuals > 2 > cash Flow > change In Working Capital
1477535
Annuals > 2 > cash Flow > cash From Operations
-1592080
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
1172923
Annuals > 2 > cash Flow > net Change In Cash
-419157
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.25157692464915665
Annuals > 2 > ratios > PB
-1.2653339225223879
Annuals > 2 > ratios > ROE
1599.642295891641
Annuals > 2 > ratios > ROA
-201.62822943490193
Annuals > 2 > ratios > FCF
-1592080
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2022-03-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
1855947
Annuals > 3 > income Statement > operating Income
-1853659
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-1858234
Annuals > 3 > income Statement > net Income
-1858234
Annuals > 3 > income Statement > eps
-0.14579851472148106
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
12745219
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-1853659
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-4575
Annuals > 3 > income Statement > currency_symbol
CAD
Annuals > 3 > balance Sheet > cash
1750851
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
39546
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
1832013
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
1832013
Annuals > 3 > balance Sheet > payables
36888
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
131762
Annuals > 3 > balance Sheet > equity
1700251
Annuals > 3 > balance Sheet > currency_symbol
CAD
Annuals > 3 > cash Flow > net Income
-1858234
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
129744
Annuals > 3 > cash Flow > cash From Operations
-1396421
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-32039
Annuals > 3 > cash Flow > cash From Financing
-1627576
Annuals > 3 > cash Flow > net Change In Cash
-3056038
Annuals > 3 > cash Flow > currency_symbol
CAD
Annuals > 3 > ratios > PE
-0.14579851472148106
Annuals > 3 > ratios > PB
0.1491720093680286
Annuals > 3 > ratios > ROE
-109.29174574812777
Annuals > 3 > ratios > ROA
-101.43126713620482
Annuals > 3 > ratios > FCF
-1396421
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.40236831154706787
Valuation > metrics > PB
0.002524026430434386
Valuation > final Score
70
Valuation > verdict
99.7% Undervalued
Profitability > metrics > ROE
-6.3474265819628535
Profitability > metrics > ROA
-9.872972577988861
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.0794692745315464
Risk > metrics > Interest Coverage
-547.1511078823102
Risk > final Score
-2129
Risk > verdict
High
Liquidity > metrics > Current Ratio
32.346291145895165
Liquidity > metrics > Quick Ratio
32.346291145895165
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
70
Prev Valuations > 2
50
Prev Profitabilities > 0
34
Prev Profitabilities > 1
34
Prev Profitabilities > 2
55
Prev Risks > 0
-1216
Prev Risks > 1
-1216
Prev Risks > 2
5
Prev Liquidities > 0
44
Prev Liquidities > 1
100
Prev Liquidities > 2
30
Updated At
2026-01-20T22:22:26.764Z
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ARecap Report: What’s the beta of NESR stock - July 2025 Macro Moves & Verified Trade Idea Suggestions baoquankhu1.vn
Read more →Whale Trades: Can PSAPRH lead its sector in growth - Weekly Market Summary & Weekly Top Performers Watchlists baoquankhu1.vn
Read more →Showing 2 of 9
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Psyence Biomedical Ltd. Warrant
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.